 |
|
|
| |
Low Proportion of Individuals Develop Metabolic Syndrome (MetS) or Hepatic Fibrosis After Switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed Patients: A Post Hoc Metabolic Analysis
|
| |
| |
IAS 2021 July 18-22
Keith Dunn,1 Amanda Gibson,1,* Erika Van Landuyt,2 Shubin Sheng,3 Donghan Luo,3 Jiyun Cai,3 Bryan Baugh4
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Janssen Research & Development, Beerse, Belgium; 3Janssen Research & Development, LLC, Titusville, NJ, USA; 4Janssen Research & Development, LLC, Raritan, NJ, USA.
|
| |
|
|
|
|
|
